Heidi Brié

Heidi Brié

Auto-generated profile, based on publicly available information

Heidi Brié

Medical Department, Novartis Pharma, Vilvoorde, Belgium

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
EAElisabeth Van Aken
Elisabeth Van Aken
MFMérédis Favreau
Mérédis Favreau
EREva Ramboer
Eva Ramboer
KDKris Denhaerynck
Kris Denhaerynck
KMKaren MacDonald
Karen MacDonald
HBHeidi Brié
Heidi Brié
Aim: Evaluate long-term real-world treatment patterns and associated effectiveness and safety outcomes in patients with diabetic macular edema (DME) treated ≥ 36 months with 0.5mg ranibizumab. Methods: Open-label observational effectiveness study in 9 Belgian clinics. Included were primary treated eyes of 55 DME patients between August 2014 and March 2015 and followed for 3.5± 1.8 years. Eyes were 21.8% treatment (TX)-naïve, 9.1% non-naïve with exclusive prior anti-VEGF treatment (PRIOR-anti-VEGF), and 63.6% non-naïve with other prior treatments (PRIOR-other). Intravitreal injections with ranibizumab were administered per ophthalmologists’ best clinical judgment. Trend testing of changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) over time occurred using mixed regression analysis. Results: The mean±SD number of treatments in the first year was 5.1± 3.0 (TX-naïve), 4.5± 2.7 (PRIOR-anti-VEGF) and 5.6± 3.1 (PRIOR-other). At 12 months, BCVA increased by 8.9± 16.4 letters from 59.7± 9.3 at baseline in TX-naïve (p< 0.0001), by 11.8± 9.9 from 61.6± 8.5 in PRIOR-anti-VEGF (p=0.03), and by 4.2± 10.6 from 58.2± 14.6 in PRIOR-other groups (p=0.0002). BCVA remained stable for the remainder of follow-up in all groups. CRT decreased over the first 2 months by monthly rates of − 43.8μm in TX-naïve (p=0.04), − 75.7μm in PRIOR-anti-VEGF (p=0.02), and − 65.8μm in PRIOR-other eyes (p=0.0003), showing stability afterwards. No unknown adverse events were recorded; a painful eye following injection was registered with a possible relationship to the treatment. Conclusion: This real-world study confirms the effectiveness of ranibizumab in preventing a decline in BCVA and demonstrated initial improvement and subsequent retention of BCVA in DME patients ≥ 36 months. Ranibizumab initially reduced and then maintained CRT. However, these data reveal that treatment intensity and BCVA and CRT outcomes are lower than those found in early efficacy trials. Under-treatment likely accounts for this efficacy-effectiveness gap. Yet, intravitreal ranibizumab is an effective and safe long-term treatment for DME under conditions of significant heterogeneity in patients and treatment patterns.

1 June 2020 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
ALAnita M Leys
Anita M Leys
EREva Ramboer
Eva Ramboer
MFMérédis Favreau
Mérédis Favreau
KDKris Denhaerynck
Kris Denhaerynck
KMKaren MacDonald
Karen MacDonald
HBHeidi Brié
Heidi Brié
Purpose: To evaluate long-term, real-world treatment patterns and outcomes of ranibizumab 0.5 mg for neovascular age-related macular degeneration (nAMD) in a Belgian cohort. Patients and Methods: This Belgian (BE) cohort of the 5-year global observational LUMINOUS study included 229 patients with nAMD. Outcomes included visual acuity (VA), central retinal thickness (CRT) and safety. Results: The mean age was 79.5± 7.7 years. The majority of patients (67.7%) were female and all patients were Caucasian. Most patients previously received ranibizumab with only 17.5% of patients being treatment-naïve. The injection frequency declined over time irrespective of prior treatment status (p< 0.0001), with treatment-naïve eyes receiving a mean of 4.2± 2.9 yearly injections and prior-ranibizumab eyes 3.6± 2.7. Regression analysis confirmed first-year VA increases for treatment-naïve eyes (p=0.002) followed by a slight decrease of − 1.8 letters per year. For prior-ranibizumab eyes, the visual changes over 1 year were statistically non-significant (p=0.90) but declined slightly after year one (p< 0.0001). Anatomically, the CRT of treatment-naïve eyes decreased over time from baseline (p< 0.0001), whereas the CRT of prior-ranibizumab eyes remained stable (p=0.43). No new safety findings were identified. Conclusion: LUMINOUS-BE reconfirms the well-characterized benefit-risk profile of ranibizumab for nAMD treatment. The observed low injection frequency reflects a need for more rigorous treatment in real-world settings. Clinical Trial Registration: NCT01318941.

25 September 2017 in International Journal of Chronic Diseases
Verified
Journal Article
Open access
PDF file
NANoha Ashy
Noha Ashy
TNThanh-Nga Nguyen
Thanh-Nga Nguyen
KDKris Denhaerynck
Kris Denhaerynck
MGMahdi Gharaibeh
Mahdi Gharaibeh
AAAbdulaziz Alhossan
Abdulaziz Alhossan
IAIvo Abraham
Ivo Abraham
We pooled data from 6 valsartan-related studies including 3,658 diabetic and 11,624 nondiabetic patients to evaluate blood pressure (BP) outcomes after approximately 90 days of second- or later-line valsartan treatment. Hierarchical linear and logistic regressions were applied to identify determinants of BP outcomes. Similar reductions in BP values and similar BP control rates were achieved in both groups after approximately 90 days of therapy. The modeling analyses identified several common and different patient- and physician-related determinants of BP outcomes for both groups, many of which are modifiable or clinically manageable. Through varying in terms of association and influence between the diabetic and nondiabetic groups, patient-related determinants included age, BP at diagnosis of hypertension, risk factors, valsartan regimen, concomitant antihypertensive treatment, and adherence; and physician-related determinants included gender, years in practice, and hypertension management. In summary, in both diabetic and nondiabetic patients, the use of valsartan-centric treatment regimens in second- or later-line antihypertensive treatment is associated with significant reductions in BP level and improvement in BP control. The determinants identified in modeling provide guidance to clinicians in the common and differential management of hypertension in diabetic and nondiabetic patients.